AbbVie (NYSE:ABBV) and Genmab (GMAB) on Saturday offered newest trial information for his or her lymphoma drug candidate epcoritamab in sufferers with difficult-to-treat relapsed/refractory (R/R) follicular lymphoma (FL).
Up to date information from Part 1/2 EPCORE NHL-1 research, offered on the sixty fifth American Society of Hematology congress, confirmed that sufferers handled with epcoritamab skilled 82% total response charges, together with 63% full response charges.
The info included an optimized, step-up dosing schedule displaying diminished incidence and severity of cytokine launch syndrome, a notable aspect impact from immune-engaging most cancers therapies. No new security alerts had been detected.
Epcoritamab is a T-cell participating bispecific antibody developed with Genmab (GMAB) expertise. Each AbbVie (ABBV) and Genmab (GMAB) share business rights for the drug within the U.S. and Japan.
The drug obtained breakthrough remedy designation from the U.S. FDA final month for therapy of relapsed or refractory follicular lymphoma.